Download PDF
Semin intervent Radiol 2024; 41(03): 309-316
DOI: 10.1055/s-0044-1787835
Clinical Corner

Treatment of Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Systemic Therapy

Harsh Khilwani
1   University of Illinois College of Medicine, Chicago, Illinois
,
Sarah Stettner
1   University of Illinois College of Medicine, Chicago, Illinois
,
Kyle Sonnabend
2   Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois
,
Yolande Chen
1   University of Illinois College of Medicine, Chicago, Illinois
2   Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois
,
Shikha Jain
1   University of Illinois College of Medicine, Chicago, Illinois
2   Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois
,
Ron C. Gaba
1   University of Illinois College of Medicine, Chicago, Illinois
3   Division of Interventional Radiology, Department of Radiology, University of Illinois at Chicago, Chicago, Illinois
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide and is frequently diagnosed at intermediate or advanced stages at which curative treatments such as surgical resection or liver transplantation are not possible. For patients with later diagnoses, transarterial chemoembolization (TACE) has become a mainstay of treatment, utilizing hepatic arterial embolotherapy to induce tumor ischemia and delivery cytotoxic chemotherapy. Despite this, because TACE is not a curative therapy, there remains further opportunity to enhance TACE outcomes by combination treatment with systemic therapies. The purpose of this article is to provide a brief primer on the various systemic therapies potentially used alongside TACE, including insights into the mechanistic foundations behind these combinations as well as a narrative literature review of representative clinical trials.



Publication History

Article published online:
19 August 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol 2015; 62 (05) 1187-1195
    CrossrefPubMedSearch in Google Scholar
  • 2 Balogh J, Victor III D, Asham EH. et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016; 3: 41-53
    CrossrefPubMedSearch in Google Scholar
  • 3 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022; 76 (03) 681-693
    CrossrefPubMedSearch in Google Scholar
  • 4 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 2014; 120 (18) 2824-2838
    CrossrefPubMedSearch in Google Scholar
  • 5 Bucalau AM, Tancredi I, Verset G. In the era of systemic therapy for hepatocellular carcinoma is transarterial chemoembolization still a card to play?. Cancers (Basel) 2021; 13 (20) 5129
    CrossrefPubMedSearch in Google Scholar
  • 6 Vilgrain V, Sibert A, Zappa M, Belghiti J. Sequential arterial and portal vein embolization in patients with cirrhosis and hepatocellular carcinoma: the Hospital Beaujon experience. Semin Intervent Radiol 2008; 25 (02) 155-161
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis 2016; 17 (08) 510-517
    CrossrefPubMedSearch in Google Scholar
  • 8 Melchiorre F, Patella F, Pescatori L. et al. DEB-TACE: a standard review. Future Oncol 2018; 14 (28) 2969-2984
    CrossrefPubMedSearch in Google Scholar
  • 9 Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 2022; 10 (01) 3
    CrossrefPubMedSearch in Google Scholar
  • 10 da Fonseca LG, Reig M, Bruix J. Tyrosine kinase inhibitors and hepatocellular carcinoma. Clin Liver Dis 2020; 24 (04) 719-737
    CrossrefPubMedSearch in Google Scholar
  • 11 Zeng Z, Lu Q, Liu Y. et al. Effect of the hypoxia inducible factor on sorafenib resistance of hepatocellular carcinoma. Front Oncol 2021; 11: 641522
    CrossrefPubMedSearch in Google Scholar
  • 12 Li X, Wang Y, Ye X, Liang P. Locoregional combined with systemic therapies for advanced hepatocellular carcinoma: an inevitable trend of rapid development. Front Mol Biosci 2021; 8: 635243
    CrossrefPubMedSearch in Google Scholar
  • 13 Rini BI. Sorafenib. Expert Opin Pharmacother 2006; 7 (04) 453-461
    CrossrefPubMedSearch in Google Scholar
  • 14 Granito A, Forgione A, Marinelli S. et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021; 14: 17 562848211016959
    CrossrefPubMedSearch in Google Scholar
  • 15 Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z. Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 2006; 41 (06) 516-521
    CrossrefPubMedSearch in Google Scholar
  • 16 Kudo M, Imanaka K, Chida N. et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47 (14) 2117-2127
    CrossrefPubMedSearch in Google Scholar
  • 17 Lee TY, Lin CC, Chen CY. et al. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: a post hoc analysis of the START trial. Medicine (Baltimore) 2017; 96 (37) e7655
    CrossrefPubMedSearch in Google Scholar
  • 18 Geschwind JF, Kudo M, Marrero JA. et al. TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology 2016; 279 (02) 630-640
    CrossrefPubMedSearch in Google Scholar
  • 19 Kudo M, Ueshima K, Ikeda M. et al. TACTICS: final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). JCO 2021; 39 (3, Suppl): 270-270
    CrossrefPubMedSearch in Google Scholar
  • 20 Kudo M, Cheng AL, Park JW. et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 2018; 3 (01) 37-46
    CrossrefPubMedSearch in Google Scholar
  • 21 Kudo M, Han G, Finn RS. et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 2014; 60 (05) 1697-1707
    CrossrefPubMedSearch in Google Scholar
  • 22 Choi NR, Kim JY, Hong JH. et al. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2022; 22 (01) 135
    CrossrefPubMedSearch in Google Scholar
  • 23 Peng Z, Fan W, Zhu B, Li J, Kuang M. Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: a phase 3, multicenter, randomized controlled trial. JCO 2022; 40 (4, Suppl): 380-380
    CrossrefPubMedSearch in Google Scholar
  • 24 Lencioni R, Llovet JM, Han G. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 2016; 64 (05) 1090-1098
    CrossrefPubMedSearch in Google Scholar
  • 25 Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JFH. Open-label single-arm phase II trial of sorafenib therapy with drug-eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: clinical results. Radiology 2015; 277 (02) 594-603
    CrossrefPubMedSearch in Google Scholar
  • 26 Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment. Gene Expr 2020; 20 (01) 53-65
    CrossrefPubMedSearch in Google Scholar
  • 27 Chapiro J, Wood LD, Lin M. et al. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 2014; 273 (03) 746-758
    CrossrefPubMedSearch in Google Scholar
  • 28 Finn RS, Qin S, Ikeda M. et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
    CrossrefPubMedSearch in Google Scholar
  • 29 Duffy AG, Ulahannan SV, Makorova-Rusher O. et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017; 66 (03) 545-551
    CrossrefPubMedSearch in Google Scholar
  • 30 Fulgenzi CAM, Cortellini A, D'Alessio A. et al. A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL. JCO 2022; 40 (16, Suppl): e16195-e16195
    CrossrefPubMedSearch in Google Scholar
  • 31 Saborowski A, Waldschmidt D, Hinrichs J. et al. IMMUTACE: a biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—updated efficacy results. JCO 2022; 40 (16, Suppl): 4116-4116
    CrossrefPubMedSearch in Google Scholar
  • 32 Kloeckner R, Galle PR, Bruix J. Local and regional therapies for hepatocellular carcinoma. Hepatology 2021; 73 (Suppl. 01) 137-149
    CrossrefPubMedSearch in Google Scholar
  • 33 Sangro B, Kudo M, Qin S. et al. P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1. Ann Oncol 2020; 31: S202-S203
    CrossrefPubMedSearch in Google Scholar
  • 34 Yasuda S, Sho M, Yamato I. et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 2013; 172 (03) 500-506
    CrossrefPubMedSearch in Google Scholar
  • 35 El-Khoueiry AB, Llovet JM, Vogel A. et al. LEAP-012 trial in progress: transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). JCO 2022; 40 (4, Suppl): TPS494-TPS494
    CrossrefPubMedSearch in Google Scholar
  • 36 Kudo M, Guo Y, Hua Y. et al. TALENTACE: a phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma. JCO 2022; 40 (4, Suppl): TPS487-TPS487
    CrossrefPubMedSearch in Google Scholar
  • 37 Ben Khaled N, Seidensticker M, Ricke J. et al. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol 2022; 18 (12) 1423-1435
    CrossrefPubMedSearch in Google Scholar
  • 38 Ponziani FR, Santopaolo F, Posa A. et al. SIRT in 2025. Cardiovasc Intervent Radiol 2022; 45 (11) 1622-1633
    CrossrefPubMedSearch in Google Scholar
  • 39 Lencioni R. et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Journal of Clinical Oncology 2024;42(03):suppl. Doi.org/10.1200/JCO.2024.42.3_suppl.LBA432
    PubMed
  • 40 Chao Y, Chung YH, Han G. et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer 2015; 136 (06) 1458-1467
    CrossrefPubMedSearch in Google Scholar
  • 41 Meyer T, Fox R, Ma YT. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2 (08) 565-575
    CrossrefPubMedSearch in Google Scholar